GO:0050650 chondroitin sulfate proteoglycan biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050650 describes the biosynthesis of chondroitin sulfate proteoglycans (CSPGs), which are core proteins carrying O-linked chondroitin sulfate glycosaminoglycan chains built from repeating glucuronic acid and N-acetylgalactosamine units.
• The pathway begins with a tetrasaccharide linker (xylose-galactose-galactose-glucuronate) attached to serine/threonine residues of the core protein, followed by polymerization and sulfation of the chondroitin sulfate chain.
• CSPGs such as CSPG4 (NG2) and neurocan are critical in neural development, regeneration, and cancer progression.
• CSPG4 is an attractive target for antibody-based immunotherapy and CAR-T cell therapies in melanoma, glioblastoma, and triple-negative breast cancer.
• Sulfation patterns, particularly 4,6-sulfation of chondroitin sulfate, regulate biological functions such as sympathetic nerve regeneration after myocardial infarction.
• CRISPR-based models (knockout, knock-in, overexpression) enable functional dissection of CSPG biosynthetic enzymes and their roles in disease.
Description
Chondroitin sulfate proteoglycans (CSPGs) are a major class of extracellular matrix molecules that consist of a core protein covalently linked to one or more chondroitin sulfate glycosaminoglycan chains. The biosynthetic process that generates these complex molecules is captured by the Gene Ontology term GO:0050650, chondroitin sulfate proteoglycan biosynthetic process. This process is essential for building the structural and signaling properties of CSPGs, which are involved in neural development, tissue repair, and cancer progression. Understanding the molecular steps and regulatory mechanisms of CSPG biosynthesis is critical for researchers studying extracellular matrix biology, neurobiology, and oncology. The biosynthesis of CSPGs requires a coordinated series of enzymatic reactions that assemble the tetrasaccharide linker, polymerize the chondroitin sulfate chain, and add sulfate groups at specific positions. These modifications determine the functional diversity of CSPGs, influencing their interactions with growth factors, receptors, and other matrix components. Dysregulation of CSPG biosynthesis has been implicated in diseases ranging from gliomas to myocardial infarction, making it a target for therapeutic intervention. Recent advances in immunotherapy have highlighted CSPG4 as a promising tumor-associated antigen, driving interest in the biosynthetic pathways that produce it. This article provides a comprehensive overview of GO:0050650, covering its definition, molecular mechanisms, key genes, disease relevance, and research methodologies, with a focus on CRISPR-based approaches for functional studies.
chondroitin sulfate proteoglycan biosynthetic process At A Glance
| GO ID | GO:0050650 |
|---|---|
| GO term | chondroitin sulfate proteoglycan biosynthetic process |
| Ontology | biological_process |
| Synonym | chondroitin sulfate proteoglycan anabolism; chondroitin sulfate proteoglycan biosynthesis; chondroitin sulfate proteoglycan formation; chondroitin sulfate proteoglycan synthesis; chondroitin sulphate proteoglycan biosynthesis; chondroitin sulphate proteoglycan biosynthetic process |
| Major function | Synthesis of chondroitin sulfate proteoglycans, which are key components of the extracellular matrix and cell surface |
| Key enzymes | Xylosyltransferases, galactosyltransferases, glucuronyltransferases, and sulfotransferases |
| Core proteins | CSPG4 (NG2), neurocan, versican, aggrecan, and others |
| Linker structure | Tetrasaccharide linker: xylose-galactose-galactose-glucuronate attached to serine/threonine |
| Chain composition | Repeating disaccharide: beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine, with O-sulfation |
What Is GO:0050650?
GO:0050650, chondroitin sulfate proteoglycan biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of chondroitin sulfate proteoglycans. These molecules consist of a core protein linked to a chondroitin sulfate glycosaminoglycan chain. The chondroitin sulfate chain is composed of repeating disaccharide units of beta-(1,4)-D-glucuronic acid and beta-(1,3)-N-acetyl-D-galactosamine, where the N-acetyl-D-galactosamine can be O-sulfated. The chondroitin sulfate chains are covalently attached to serine or threonine residues of the core protein via a tetrasaccharide linker sequence (xylose-galactose-galactose-glucuronate).
Why Is chondroitin sulfate proteoglycan biosynthetic process Important in Cell Biology?
The chondroitin sulfate proteoglycan biosynthetic process is fundamental to the formation of CSPGs, which play critical roles in cell adhesion, migration, proliferation, and differentiation. CSPGs are major constituents of the extracellular matrix in the nervous system, where they regulate axon guidance and synaptic plasticity. In cancer, CSPG4 is overexpressed in melanoma, glioblastoma, and breast cancer, promoting tumor growth and serving as a target for immunotherapies. Additionally, sulfation patterns of chondroitin sulfate chains influence nerve regeneration after myocardial infarction. Thus, understanding this biosynthetic pathway is essential for developing therapeutic strategies in oncology, neurology, and regenerative medicine.
• CSPGs are essential for neural development and axon guidance, with neurocan being a major brain CSPG.
• CSPG4 is a promising target for antibody-based immunotherapy and CAR-T cell therapies in multiple cancers.
• Chondroitin sulfate sulfation at specific positions regulates sympathetic nerve regeneration after myocardial infarction.
• CSPG biosynthesis influences the tumor microenvironment and cancer cell proliferation in gliomas.
• Dysregulation of CSPG biosynthesis is linked to neurodegenerative disorders and impaired tissue repair.
• The pathway provides potential therapeutic targets for modulating extracellular matrix in disease.
• CSPGs can modulate growth factor signaling and receptor activation.
• Understanding CSPG biosynthesis aids in the design of biomaterials and tissue engineering strategies.
• CSPG4-targeting BiTE antibodies show potency dependent on epitope distance and antigen size.
• CRISPR screening can identify novel regulators of CSPG biosynthesis for drug discovery.
What Happens During chondroitin sulfate proteoglycan biosynthetic process?
Initiation and Tetrasaccharide Linker Assembly
In simple terms: The first step builds a short sugar linker that attaches the chondroitin sulfate chain to the core protein.
The biosynthesis of chondroitin sulfate proteoglycans begins with the transfer of xylose to specific serine or threonine residues on the core protein, catalyzed by xylosyltransferase. This is followed by the sequential addition of two galactose residues and one glucuronic acid residue to form the tetrasaccharide linker (xylose-galactose-galactose-glucuronate). This linker serves as the primer for chondroitin sulfate chain elongation. The core proteins, such as CSPG4 and neurocan, are synthesized in the endoplasmic reticulum and transported to the Golgi apparatus where these modifications occur.
Chondroitin Sulfate Chain Polymerization
In simple terms: The linker is extended by adding repeating sugar units to form the long chondroitin sulfate chain.
After linker assembly, the chondroitin sulfate chain is polymerized by the alternating addition of glucuronic acid and N-acetylgalactosamine residues. This step is catalyzed by chondroitin sulfate synthases, which are glycosyltransferases located in the Golgi apparatus. The repeating disaccharide unit is beta-(1,4)-D-glucuronic acid-beta-(1,3)-N-acetyl-D-galactosamine. The length and number of chains vary depending on the core protein and cell type, contributing to the structural diversity of CSPGs.
Sulfation of the Chondroitin Sulfate Chain
In simple terms: Sulfate groups are added to specific positions on the sugar units, which changes how the CSPG interacts with other molecules.
Sulfation is a critical modification that occurs during chondroitin sulfate biosynthesis. Sulfotransferases add sulfate groups to the N-acetylgalactosamine residues, typically at the 4-O or 6-O positions, generating chondroitin-4-sulfate or chondroitin-6-sulfate. The sulfation pattern determines the functional properties of the CSPG, including its binding to growth factors and its role in nerve regeneration. For example, 4,6-sulfation of CSPG4 regulates sympathetic nerve regeneration after myocardial infarction.
Transport and Secretion of Mature CSPGs
In simple terms: Once fully built, the CSPG is transported to the cell surface or secreted into the extracellular matrix.
After synthesis and modification in the Golgi, mature CSPGs are transported to the cell surface or secreted into the extracellular matrix. This trafficking is essential for their biological functions. For instance, chondroitin sulfate accelerates the trans-Golgi-to-surface transport of proteoglycan amyloid precursor protein, indicating a role for CSPGs in protein trafficking. The mature CSPGs can then interact with cell surface receptors, growth factors, and other matrix components to modulate cellular behavior.
Key Genes Involved in GO:0050650 chondroitin sulfate proteoglycan biosynthetic process
The following genes and proteins are key players in the chondroitin sulfate proteoglycan biosynthetic process, including core proteins and enzymes involved in chain assembly and modification.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CSPG4 | Core protein of chondroitin sulfate proteoglycan 4 (NG2) | Target for immunotherapy in melanoma, glioblastoma, and breast cancer |
| NCAN | Core protein neurocan, a brain-specific CSPG | Involved in neural development and regeneration |
| XYLT1 | Xylosyltransferase 1, initiates linker assembly | Mutations cause skeletal disorders; potential target for modulating CSPG biosynthesis |
| XYLT2 | Xylosyltransferase 2, initiates linker assembly | Similar to XYLT1, involved in proteoglycan biosynthesis |
| B4GALT7 | Galactosyltransferase I, adds galactose to linker | Defects cause Ehlers-Danlos syndrome-like disorders |
| B3GALT6 | Galactosyltransferase II, adds second galactose | Mutations linked to connective tissue disorders |
| B3GAT3 | Glucuronyltransferase, completes tetrasaccharide linker | Defects cause skeletal and connective tissue abnormalities |
| CHSY1 | Chondroitin sulfate synthase 1, polymerizes chain | Regulates chondroitin sulfate chain length and sulfation |
| CHSY3 | Chondroitin sulfate synthase 3, polymerizes chain | Isoform with distinct tissue distribution |
| CHPF | Chondroitin polymerizing factor | Required for chondroitin sulfate polymerization |
| CHPF2 | Chondroitin polymerizing factor 2 | Isoform involved in chain elongation |
| UST | Uronosyl 2-sulfotransferase | Adds sulfate to glucuronic acid residues |
| CHST3 | Carbohydrate sulfotransferase 3 | Adds 6-O-sulfate to N-acetylgalactosamine |
| CHST11 | Carbohydrate sulfotransferase 11 | Adds 4-O-sulfate to N-acetylgalactosamine |
| CHST12 | Carbohydrate sulfotransferase 12 | Adds 4-O-sulfate to N-acetylgalactosamine |
| CHST13 | Carbohydrate sulfotransferase 13 | Adds 4-O-sulfate to N-acetylgalactosamine |
| CHST14 | Carbohydrate sulfotransferase 14 | Adds 4-O-sulfate; mutations cause Ehlers-Danlos syndrome |
| CHST15 | Carbohydrate sulfotransferase 15 | Adds 4,6-disulfate to N-acetylgalactosamine; regulates nerve regeneration |
How Is chondroitin sulfate proteoglycan biosynthetic process Regulated?
The chondroitin sulfate proteoglycan biosynthetic process is regulated at multiple levels, including transcriptional control of core protein and enzyme genes, post-translational modifications of enzymes, and availability of substrates such as UDP-sugars and PAPS (3'-phosphoadenosine-5'-phosphosulfate). Sulfation patterns are dynamically regulated by the expression and activity of specific sulfotransferases, which can be influenced by growth factors and cytokines. For example, 4,6-sulfation of CSPG4 is regulated during sympathetic nerve regeneration after myocardial infarction. Additionally, the transport of CSPGs through the Golgi can be modulated by interacting proteins, as seen with amyloid precursor protein. However, the precise regulatory mechanisms, including potential roles of mTOR or integrated stress response, remain to be fully elucidated for this pathway.
chondroitin sulfate proteoglycan biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CSPG4 | Melanoma, glioblastoma, triple-negative breast cancer | CSPG4 knockout melanoma cell lines; CAR-T co-culture assays |
| NCAN | Neural development and axon regeneration | Neurocan knockout mice; primary neuron cultures |
| CHST15 | Sympathetic nerve regeneration after myocardial infarction | Chst15 knockout mice; myocardial infarction models |
| CSPG4 | Glioma progression and stemness | Patient-derived glioma xenografts; CSPG4 knockdown |
| APP | Alzheimer's disease; protein trafficking | APP overexpression in neuronal cells; chondroitin sulfate treatment |
CSPG4 in Cancer and Immunotherapy
CSPG4 is overexpressed in several malignancies, including melanoma, glioblastoma, and triple-negative breast cancer, where it promotes tumor growth and survival. Its high surface expression makes it an attractive target for antibody-based immunotherapies, such as BiTE antibodies and CAR-T cells. Preclinical studies have shown that CSPG4-targeting CAR-macrophages inhibit melanoma growth, and co-targeting B7-H3 and CSPG4 with Pan-CAR-T cells is effective against triple-negative breast cancer. These findings underscore the importance of CSPG biosynthesis in cancer and the therapeutic potential of targeting CSPG4.
Neurocan in Neural Development and Regeneration
Neurocan is a brain-specific chondroitin sulfate proteoglycan that plays a role in neural development and regeneration. It is a major component of the extracellular matrix in the central nervous system and can inhibit axon regeneration after injury. Modulating neurocan biosynthesis or its sulfation pattern may provide strategies for promoting neural repair. Additionally, chondroitin sulfate proteoglycans are involved in synaptic plasticity and memory formation.
Chondroitin Sulfate Sulfation in Cardiovascular Repair
After myocardial infarction, chondroitin sulfate proteoglycan 4,6-sulfation regulates sympathetic nerve regeneration. This suggests that manipulating CSPG sulfation could enhance cardiac repair and regeneration. The study by Blake et al. (2022) demonstrated that specific sulfation patterns are critical for nerve sprouting and functional recovery, highlighting the therapeutic potential of targeting sulfotransferases.
CSPG4 in Gliomas
CSPG4 is expressed in gliomas and contributes to tumor progression and invasion. It is considered a marker of glioma stem-like cells and a potential target for therapy. Schiffer et al. (2018) reviewed the significance of CSPG4 in human gliomas, emphasizing its role in cell migration and proliferation. Targeting CSPG4 or its biosynthetic pathway may offer new avenues for glioma treatment.
From chondroitin sulfate proteoglycan biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CSPG4 loss affect melanoma growth? | CSPG4 knockout melanoma cell lines and xenograft mouse models |
| What is the role of CHST15 in nerve regeneration? | Chst15 knockout mice subjected to myocardial infarction |
| How does neurocan regulate axon guidance? | Neurocan knockout mice and in vitro axon outgrowth assays |
| Can CSPG4-specific CAR-T cells target glioblastoma? | Patient-derived glioblastoma cells and orthotopic xenografts |
| Does chondroitin sulfate affect APP trafficking? | APP-overexpressing neuronal cells treated with chondroitin sulfate |
| What is the impact of CSPG4 sulfation on immune recognition? | Point mutations in sulfotransferase genes in cancer cells; co-culture with immune cells |
How to Study the chondroitin sulfate proteoglycan biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression levels | Profiling CSPG pathway genes in cancer or neural tissues |
| LC-MS/MS glycomics | Chondroitin sulfate disaccharide composition and sulfation | Characterizing CSPG modifications in disease models |
| Fluorescence microscopy | Intracellular trafficking and localization | Tracking CSPG transport from Golgi to surface |
| CRISPR knockout | Loss-of-function phenotypes | Assessing the role of CSPG4 in tumor growth |
| CRISPR knock-in | Tagged or mutant protein expression | Studying sulfotransferase specificity |
| CAR-T cytotoxicity assay | Immune cell-mediated killing | Evaluating CSPG4-targeting immunotherapies |
| Western blot | Protein expression and modification | Validating CSPG core protein levels |
| Flow cytometry | Cell surface CSPG expression | Sorting CSPG4-positive cells for functional studies |
Genomic and Transcriptomic Profiling
RNA sequencing (RNA-seq) can be used to quantify the expression of genes involved in chondroitin sulfate proteoglycan biosynthesis, such as CSPG4, NCAN, and sulfotransferases, across different tissues or disease states. Single-cell RNA-seq can resolve cell-type-specific expression patterns in complex tissues like tumors or brain. These methods help identify transcriptional changes that correlate with disease progression or treatment response.
Proteomic and Glycomic Analyses
Mass spectrometry-based proteomics and glycomics can characterize the core proteins and chondroitin sulfate chains of CSPGs. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can determine sulfation patterns and disaccharide composition, which are critical for function. These techniques allow researchers to assess how genetic or pharmacological perturbations alter CSPG biosynthesis.
Imaging and Trafficking Studies
Fluorescence microscopy and live-cell imaging can track the intracellular transport of CSPGs from the Golgi to the cell surface. For example, chondroitin sulfate accelerates trans-Golgi-to-surface transport of amyloid precursor protein, which can be visualized using fluorescently tagged proteins. These methods provide spatial and temporal insights into CSPG trafficking and secretion.
Functional Assays and CRISPR Screens
CRISPR-based knockout, knock-in, and overexpression models enable functional studies of CSPG biosynthetic genes. For instance, knocking out CSPG4 in cancer cells can reveal its role in proliferation and immune evasion. High-throughput CRISPR screens can identify novel regulators of CSPG biosynthesis and sulfation, accelerating target discovery.
How CRISPR Can Be Used to Study GO:0050650 chondroitin sulfate proteoglycan biosynthetic process
Knockout
CRISPR knockout of genes involved in chondroitin sulfate proteoglycan biosynthesis, such as CSPG4 or CHST15, can elucidate their roles in disease. For example, CSPG4 knockout in melanoma cells reduces tumor growth and enhances immune recognition. Knockout of Chst15 in mice impairs sympathetic nerve regeneration after myocardial infarction, demonstrating the importance of sulfation. These models are valuable for target validation and drug discovery.
Point Mutation
CRISPR-mediated point mutations can be used to study the specific roles of amino acid residues or sulfation sites in CSPG function. For instance, mutating the serine/threonine residues that serve as attachment sites for chondroitin sulfate chains can prevent proteoglycan formation. Similarly, point mutations in sulfotransferases can alter enzyme activity and sulfation patterns, providing insights into structure-function relationships.
Knock-in
Knock-in of tagged or reporter genes allows visualization and tracking of CSPGs in live cells. For example, inserting a fluorescent tag into the CSPG4 locus enables real-time imaging of its trafficking and localization. Knock-in of disease-associated mutations can also model human disorders related to CSPG biosynthesis, such as Ehlers-Danlos syndrome caused by CHST14 mutations.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression constructs can drive high-level expression of CSPG core proteins or biosynthetic enzymes. Overexpression of CSPG4 in cancer cells can enhance tumorigenicity and resistance to therapy. Conversely, overexpression of sulfotransferases can modify chondroitin sulfate sulfation patterns, affecting nerve regeneration and other processes. These models are useful for gain-of-function studies and drug screening.
How EDITGENE Supports chondroitin sulfate proteoglycan biosynthetic process Research
Researchers studying chondroitin sulfate proteoglycan biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in disease or development. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of CSPG pathway components.
Contact EDITGENE today to design your custom CRISPR model for chondroitin sulfate proteoglycan biosynthetic process research.
Frequently Asked Questions About chondroitin sulfate proteoglycan biosynthetic process
What is GO:0050650 chondroitin sulfate proteoglycan biosynthetic process?
GO:0050650 is a Gene Ontology term describing the chemical reactions and pathways that build chondroitin sulfate proteoglycans, which are core proteins linked to chondroitin sulfate glycosaminoglycan chains.
What genes are involved in chondroitin sulfate proteoglycan biosynthesis?
Key genes include core proteins like CSPG4 and NCAN, as well as enzymes such as XYLT1, CHSY1, and various sulfotransferases (CHST3, CHST11, CHST15).
How is chondroitin sulfate proteoglycan biosynthetic process regulated?
It is regulated by transcriptional control of core protein and enzyme genes, substrate availability, and post-translational modifications. Sulfation patterns are dynamically controlled by specific sulfotransferases.
What diseases are associated with chondroitin sulfate proteoglycan biosynthesis?
Diseases include melanoma, glioblastoma, triple-negative breast cancer, neural regeneration disorders, and cardiovascular conditions after myocardial infarction.
What is the role of CSPG4 in cancer?
CSPG4 is overexpressed in several cancers and promotes tumor growth, making it a target for immunotherapies such as CAR-T cells and BiTE antibodies.
How can CRISPR be used to study chondroitin sulfate proteoglycan biosynthesis?
CRISPR knockout, knock-in, point mutation, and overexpression models allow functional dissection of genes involved in CSPG biosynthesis, including their roles in disease.
What is the tetrasaccharide linker in chondroitin sulfate proteoglycans?
The tetrasaccharide linker is a sugar sequence (xylose-galactose-galactose-glucuronate) that attaches the chondroitin sulfate chain to serine/threonine residues of the core protein.
What is the difference between chondroitin-4-sulfate and chondroitin-6-sulfate?
They differ in the position of sulfate groups on N-acetylgalactosamine; chondroitin-4-sulfate has sulfate at the 4-O position, while chondroitin-6-sulfate has it at the 6-O position. These patterns affect function.
What methods are used to study chondroitin sulfate proteoglycan biosynthesis?
Methods include RNA-seq, LC-MS/MS glycomics, fluorescence microscopy, CRISPR screens, and functional assays such as CAR-T cytotoxicity.
Why is neurocan important in the brain?
Neurocan is a brain-specific chondroitin sulfate proteoglycan that regulates neural development, axon guidance, and synaptic plasticity.
Conclusion
The chondroitin sulfate proteoglycan biosynthetic process (GO:0050650) is a complex, multi-step pathway that generates essential extracellular matrix molecules with diverse roles in development, tissue repair, and cancer. Key genes such as CSPG4 and NCAN, along with numerous biosynthetic enzymes, are critical for the structure and function of CSPGs. Dysregulation of this pathway is implicated in melanoma, glioblastoma, breast cancer, and cardiovascular disease, making it a rich area for therapeutic targeting. CRISPR-based models and advanced screening technologies are invaluable for dissecting the molecular mechanisms of CSPG biosynthesis and identifying new drug targets. EDITGENE's comprehensive services, including knockout, knock-in, point mutation, overexpression, and library screening, empower researchers to accelerate discoveries in this field. By leveraging these tools, the scientific community can further unravel the complexities of CSPG biology and translate findings into clinical applications.
References
- 1. Kurokawa T et al.. 2024. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.. Proc Jpn Acad Ser B Phys Biol Sci 100(5):293-308 PMID: 38735753
- 2. Stucchi S et al.. 2025. B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer.. J Immunother Cancer 13(5) PMID: 40425233
- 3. Greiner D et al.. 2025. Human CSPG4-targeting CAR-macrophages inhibit melanoma growth.. Oncogene 44(22):1665-1677 PMID: 40082557
- 4. Blake MR et al.. 2022. Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction.. Elife 11 PMID: 35604022
- 5. Bluemel C et al.. 2010. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.. Cancer Immunol Immunother 59(8):1197-209 PMID: 20309546
- 6. Rauch U et al.. 2001. Neurocan: a brain chondroitin sulfate proteoglycan.. Cell Mol Life Sci 58(12-13):1842-56 PMID: 11766883
- 7. Schiffer D et al.. 2018. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.. Int J Mol Sci 19(9) PMID: 30213051
- 8. Mihov D et al.. 2015. Chondroitin Sulfate Accelerates Trans-Golgi-to-Surface Transport of Proteoglycan Amyloid Precursor Protein.. Traffic 16(8):853-70 PMID: 25951880
